

Special Issue

Liver Metastasis of Cancer

Message from the Guest Editor

Liver metastases: the evolution of understanding the mechanisms, diagnosis and treatment options. This Special Issue will focus on describing historically how our understanding of the mechanisms of disease has evolved and what future directions are needed. We will also describe the evolution of the diagnosis of the disease and how new technologies, such as liquid biopsies (ctDNA, CTCs, EVs) and biobanks, have advanced our ability to diagnose the disease and its recurrence, as well as to introduce new treatment options. In another chapter, we will explore different treatment options which have arisen over the years, from chemotherapy to targeted therapy and surgical interventions, and how both modalities have improved. We will also explore the impact on overall survival and progression-free survival with respect to quality of life and the direction of clinical trials. All chapters in this Issue will focus on the impact different components have had on modeling clinical trials and their impact, the lesson learned, and the next steps. Finally, the last chapter will encompass patients' perspective on treatment options. For this, we will reach out to patient advocacy groups.

Guest Editor

Dr. Anthoula Lazaris

Department of Surgery, McGill University Health Center Research Institute, Cancer Program, Montreal, QC H4A 3J1, Canada

Deadline for manuscript submissions

closed (15 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/173917

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)